Recombinant Human Latent TGF-beta 1 Protein, CF

Name: Recombinant Human Latent TGF-beta 1 Protein, CF
Brand: R&D Systems
SKU: 299-LTB
Price: 1143 USD
Availability: InStock

R&D Systems | Catalog # 299-LTB

Submit a review

Product Documents

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems CHO-derived Recombinant Human Latent TGF-beta 1 Protein (299-LTB)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

CHO

Accession Number

P01137

Applications

Bioactivity

View all TGF-beta 1 Proteins and Enzymes »

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human TGF-beta 1 protein
Leu30-Ser390

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Leu30 (LAP) & Ala 279 (Mature)

Predicted Molecular Mass

29 kDa (LAP) & 13 kDa (Mature)

SDS-PAGE

36-42 kDa & 9-13 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA.
Recombinant Human Latent TGF-beta 1 (Catalog # 299-LTB) binds to Recombinant Human LRRC32/GARP (Catalog # 6055-LR) with an ED₅₀ of 3.00-30.0 ng/mL.

Scientific Data Images for Recombinant Human Latent TGF-beta 1 Protein, CF

Recombinant Human Latent TGF‑ beta 1 Protein Binding Activity.

Recombinant Human Latent TGF-beta 1 (Catalog # 299-LTB) binds to Recombinant Human LRRC32/GARP (6055-LR) with an ED₅₀ of 3.00‑30.0 ng/mL.

Recombinant Human Latent TGF‑ beta 1 Protein SDS-PAGE.

2 μg/lane of Recombinant Human Latent TGF‑ beta 1 Protein (Catalog # 299-LTB) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 36-42 kDa & 9-13 kDa, and 70-80 kDa and 18-26 kDa, respectively.

Formulation, Preparation, and Storage

299-LTB

Formulation	Supplied as a 0.2 μm filtered solution in PBS with Trehalose.
Shipping	The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -70 °C as supplied. 2 weeks, 2 to 8 °C under sterile conditions after opening. 3 months, -20 to -70 °C under sterile conditions after opening.

Background: TGF-beta 1

TGF- beta 1 (transforming growth factor beta 1) and the closely related TGF-beta 2 and -3 are members of the large TGF-beta superfamily. TGF- beta proteins are highly pleiotropic cytokines that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1-3). Human TGF-beta 1 cDNA encodes a 390 amino acid (aa) precursor that contains a 29 aa signal peptide and a 361 aa proprotein (4). A furin-like convertase processes the proprotein within the trans-Golgi to generate an N‑terminal 249 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF-beta 1 (4-6). Disulfide-linked homodimers of LAP and TGF-beta 1 remain non‑covalently associated after secretion, forming the small latent TGF-beta 1 complex (4-8). Purified LAP is also capable of associating with active TGF-beta with high affinity, and can neutralize TGF-beta activity (9). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (5-7). TGF-beta activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins (5, 8). The LAP portion of human TGF-beta 1 shares 91%, 92%, 85%, 86% and 88% aa identity with porcine, canine, mouse, rat and equine TGF-beta 1 LAP, respectively, while the mature human TGF-beta 1 portion shares 100% aa identity with procine, canine and bovine TGF-beta 1, and 99% aa identity with mouse, rat and equine TGF-beta 1. Although different isoforms of TGF-beta are naturally associated with their own distinct LAPs, the TGF-beta 1 LAP is capable of complexing with, and inactivating, all other human TGF-beta isoforms and those of most other species (9). Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1 (10).

References

Dunker, N. and K. Krieglstein (2000) Eur. J. Biochem. 267:6982.
Wahl, S.M. (2006) Immunol. Rev. 213:213.
Chang, H. et al. (2002) Endocr. Rev. 23:787.
Derynck, R. et al. (1985) Nature 316:701.
Dabovic, B. and D.B. Rifkin (2008) “TGF-beta Bioavailability” in The TGF-beta Family. Derynck, R. and K. Miyazono (eds): Cold Spring Harbor Laboratory Press, p. 179.
Brunner, A.M. et al. (1989) J. Biol. Chem. 264:13660.
Miyazono, K. et al. (1991) EMBO J. 10:1091.
Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
Miller, D.M. et al. (1992) Mol. Endocrinol. 6:694.
Janssens, K. et al. (2003) J. Biol. Chem. 278:7718.